Lundbeck's big reorg will help fund R&D on new antipsychotic med

As Lundbeck cuts staff and reshuffles R&D, one of its drug candidates has come out a winner. The Danish drugmaker will go solo on developing a schizophrenia med, Lu AF35700, using its reorganized balance sheet to help fund its R&D advance out of early-stage study. Report